SI1089733T1 - Use of optically pure (+)-norcisapride for treating irritable bowel syndrome - Google Patents

Use of optically pure (+)-norcisapride for treating irritable bowel syndrome

Info

Publication number
SI1089733T1
SI1089733T1 SI9930764T SI9930764T SI1089733T1 SI 1089733 T1 SI1089733 T1 SI 1089733T1 SI 9930764 T SI9930764 T SI 9930764T SI 9930764 T SI9930764 T SI 9930764T SI 1089733 T1 SI1089733 T1 SI 1089733T1
Authority
SI
Slovenia
Prior art keywords
norcisapride
bowel syndrome
irritable bowel
optically pure
treating irritable
Prior art date
Application number
SI9930764T
Other languages
English (en)
Slovenian (sl)
Inventor
Paul D. Rubin
Timothy J. Barberich
Original Assignee
Sepracor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc. filed Critical Sepracor Inc.
Publication of SI1089733T1 publication Critical patent/SI1089733T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
SI9930764T 1998-06-15 1999-06-10 Use of optically pure (+)-norcisapride for treating irritable bowel syndrome SI1089733T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8922498P 1998-06-15 1998-06-15
US12227599P 1999-03-01 1999-03-01
PCT/US1999/013099 WO1999065571A2 (fr) 1998-06-15 1999-06-10 Utilisation du (+) norcisapride optiquement pur pour traiter l'apnee, la boulimie et d'autres troubles

Publications (1)

Publication Number Publication Date
SI1089733T1 true SI1089733T1 (en) 2005-06-30

Family

ID=26780365

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930764T SI1089733T1 (en) 1998-06-15 1999-06-10 Use of optically pure (+)-norcisapride for treating irritable bowel syndrome

Country Status (26)

Country Link
US (4) US6048879A (fr)
EP (1) EP1089733B1 (fr)
JP (1) JP2002518352A (fr)
KR (3) KR20010052739A (fr)
CN (1) CN1312717A (fr)
AR (1) AR019671A1 (fr)
AT (1) ATE291427T1 (fr)
AU (1) AU4433399A (fr)
BG (1) BG105096A (fr)
BR (1) BR9911299A (fr)
CA (1) CA2333666A1 (fr)
CZ (1) CZ20004737A3 (fr)
DE (1) DE69924375T2 (fr)
ES (1) ES2237110T3 (fr)
HK (1) HK1040058A1 (fr)
HU (1) HUP0102203A3 (fr)
IL (1) IL140118A0 (fr)
IS (1) IS5756A (fr)
NO (1) NO20006357L (fr)
NZ (3) NZ535135A (fr)
PL (1) PL345275A1 (fr)
PT (1) PT1089733E (fr)
SI (1) SI1089733T1 (fr)
SK (1) SK19052000A3 (fr)
TR (7) TR200003708T2 (fr)
WO (1) WO1999065571A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US20060241164A1 (en) * 1998-02-27 2006-10-26 The Board Of Trustees Of The University Of Illinoi Pharmacological treatment for sleep apnea
JP2003522103A (ja) 1998-06-15 2003-07-22 セプラコア インコーポレーテッド 無呼吸、過食症およびその他の障害を治療するための光学的に純粋な（−）−ノルシスアプリドの使用
EP1435238A1 (fr) * 1999-03-01 2004-07-07 Sepracor Inc. Méthode de traitement de l'apnée et des troubles de l'apnée à l'aide de l'R(+)ondansétron optiquement pur
US6548082B1 (en) * 1999-03-01 2003-04-15 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
CA2868614A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7844338B2 (en) * 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US20040172084A1 (en) * 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US7444183B2 (en) * 2003-02-03 2008-10-28 Enteromedics, Inc. Intraluminal electrode apparatus and method
US7613515B2 (en) * 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
US20050070970A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Movement disorder stimulation with neural block
US20050070974A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
WO2005120363A1 (fr) * 2004-06-03 2005-12-22 Mayo Foundation For Medical Education And Research Traitement de l'obesite et dispositif associe
US20060020277A1 (en) * 2004-07-20 2006-01-26 Gostout Christopher J Gastric reshaping devices and methods
US20060020298A1 (en) * 2004-07-20 2006-01-26 Camilleri Michael L Systems and methods for curbing appetite
US7833279B2 (en) * 2004-11-12 2010-11-16 Enteromedics Inc. Pancreatic exocrine secretion diversion apparatus and method
JP2008524332A (ja) 2004-12-20 2008-07-10 コレジウム ファーマシューティカル， インク． 睡眠傷害のための医薬組成物
US7672727B2 (en) * 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
US7822486B2 (en) * 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
CA2641821C (fr) * 2006-02-16 2017-10-10 Imthera Medical, Inc. Appareil, systeme et procede rfid de traitement therapeutique d'un patient
BRPI0818654A2 (pt) 2007-10-09 2015-04-07 Imthera Medical Inc Aparelho, sistema e método para estimulação seletiva
US8428725B2 (en) 2008-10-09 2013-04-23 Imthera Medical, Inc. Method of stimulating a Hypoglossal nerve for controlling the position of a patient's tongue
AU2010318651A1 (en) 2009-11-10 2012-05-03 Imthera Medical, Inc. System for stimulating a hypoglossal nerve for controlling the position of a patient's tongue
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
US10123896B2 (en) 2014-03-06 2018-11-13 Mayo Foundation For Medical Education And Research Apparatus and methods of inducing weight loss using blood flow control

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR748807A (fr) * 1932-03-10 1933-07-10 Gulf Refining Co Perfectionnements à la fabrication d'hydrocarbures
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
CA1183847A (fr) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide; derives
US4598123A (en) * 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4800162A (en) * 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) * 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075290A (en) * 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CA2126354C (fr) * 1991-12-21 2006-07-11 Gareth John Sanger Utilisation de modulateurs de 5-ht4 pour la fabrication d'un medicament pour le traitement des maladies de la vessie
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
US5502067A (en) * 1994-02-04 1996-03-26 Morgan; Julia A. Treating apneahypopnea/snoring in humans
US5407953A (en) * 1994-02-04 1995-04-18 Morgan; Julia A. Treating apnea/hypopnea/snoring in humans
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2735475B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
JP3529102B2 (ja) * 1997-07-11 2004-05-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノート シヤツプ ５−ｈｔ３および５−ｈｔ４介在性障害に有用な（＋）−ノルシサプリド

Also Published As

Publication number Publication date
JP2002518352A (ja) 2002-06-25
WO1999065571A2 (fr) 1999-12-23
PL345275A1 (en) 2001-12-03
KR20010052739A (ko) 2001-06-25
HUP0102203A2 (hu) 2001-11-28
US6835740B2 (en) 2004-12-28
US6369079B1 (en) 2002-04-09
KR20060067986A (ko) 2006-06-20
CN1312717A (zh) 2001-09-12
TR200103056T2 (tr) 2002-06-21
WO1999065571A3 (fr) 2000-04-20
US20020147220A1 (en) 2002-10-10
NO20006357D0 (no) 2000-12-13
BG105096A (en) 2002-02-28
TR200103055T2 (tr) 2002-06-21
TR200103054T2 (tr) 2002-06-21
KR20060017570A (ko) 2006-02-23
TR200003708T2 (tr) 2001-06-21
TR200103059T2 (tr) 2002-06-21
CA2333666A1 (fr) 1999-12-23
NZ535135A (en) 2006-04-28
HK1040058A1 (zh) 2002-05-24
US6048879A (en) 2000-04-11
DE69924375D1 (de) 2005-04-28
EP1089733A2 (fr) 2001-04-11
BR9911299A (pt) 2001-03-13
NO20006357L (no) 2001-02-13
CZ20004737A3 (cs) 2001-10-17
TR200103058T2 (tr) 2002-06-21
NZ526943A (en) 2004-11-26
IS5756A (is) 2000-12-08
AU4433399A (en) 2000-01-05
HUP0102203A3 (en) 2001-12-28
TR200103057T2 (tr) 2002-06-21
SK19052000A3 (sk) 2001-06-11
AR019671A1 (es) 2002-03-13
US20050154018A1 (en) 2005-07-14
IL140118A0 (en) 2002-02-10
ATE291427T1 (de) 2005-04-15
ES2237110T3 (es) 2005-07-16
NZ508824A (en) 2003-10-31
PT1089733E (pt) 2005-08-31
EP1089733B1 (fr) 2005-03-23
DE69924375T2 (de) 2005-08-11

Similar Documents

Publication Publication Date Title
SI1089733T1 (en) Use of optically pure (+)-norcisapride for treating irritable bowel syndrome
GB2317611B (en) Heat-resistant glass composition
GB2331813B (en) Combination of optical elements
EP0907723A4 (fr) Composition enzymatique pour la dissociation tissulaire
HUP0100765A3 (en) Composition for the treatment of halitosis
AU2292701A (en) Thermal protection for methods of treating arthroscopic pathologies
KR100205768B1 (en) Stereo-selective composition of 4-acetoxyazetidinone
EP1049716A4 (fr) Purification du fibrinogene
GB9607963D0 (en) Cleansing composition
PL331366A1 (en) Composition of silicate-sodium-calcium glass
HUP9600148A2 (en) Glass composition
GB2318350B (en) Process for purification of hydrochlorofluoroethanes
SI1607090T1 (sl) Asimadolin za zdravljenje sindroma razdraĹľljivega ÄŤrevesa
IL138919A0 (en) Use of nmda antagonists for treatment of irritable bowel syndrome
PL331823A1 (en) Glass composition of silicate-sodium-calcium type
GB9610112D0 (en) Water treatment compositions
HK1041202A1 (en) Novel method of treatment
GB9928314D0 (en) Composition for the treatment of irritable bowel syndrome
IL131765A0 (en) Process for the purification of substituted p-nitrodiphenylethers
TW366106U (en) Improved structure for assist-glasses of glasses
SI1073431T1 (en) Use of nmda antagonists for treatment of irritable bowel syndrome
AU5753599A (en) Treatment of fibres
GB9824791D0 (en) Novel methods of treatment
GB2316942B (en) Purification of pentafluoroethane
EP0760660A4 (fr) Traitement de certains etats par (-)-liarozole optiquement pur